Introduction
In mammals, the Notch transmembrane receptor gene family is comprised of four members, Notch1/TAN-1, Notch2, Notch3 and Notch4/Int3 (Callahan and Egan, 2004) . The extracellular domain (ECD) is comprised of between 29 and 36 epidermal growth factor (EGF)-like repeats and three copies of a lin-12/Notch Glp motif. The intracellular domain (ICD) has a RAM23 region, seven CDC10/Ankyrin repeats and a PEST (proline, glutamate, serine, threonine-rich) region (Jeffries and Capobianco, 2000; Baron et al., 2002) . Notch4/Int3 (ICD4) is smaller than Notch1ICD and lacks the transcriptional activation domain (TAD) and cytokine response (NCR) sequence found in the Notch1ICD (Uyttendaele et al., 1996; Allenspach et al., 2002) . Upon ligand activation, the intracellular domain of Notch is proteolytically cleaved releasing the ICD domain. The ICD is subsequently translocated to the nucleus (Kopan et al., 1996) where it binds to CBF-1, displacing it from a corepressor complex comprised of histone deacetylases (HDAC) and leading to the expression of members of the Hes (Hairy Enhancer of split) (Jarriault et al., 1995; Tamura et al., 1995) and Herp (Hes-related repressor protein) gene families (Iso et al., 2001) . The Notch4 promoter (but not Notch2 or Notch3) like Hes1 contains CSL-binding elements and therefore, is also a target gene of Notch1 (Weijzen et al., 2002) . Genetic alterations of Notch1 or Notch4 that lead to the deregulated expression of the Notch ICD represent gain of function mutations that are associated with T-lymphoblastic and mammary tumorigenesis, respectively (Ellisen et al., 1991; Jhappan et al., 1992; Zagouras et al., 1995; Gallahan et al., 1996; Kiaris et al., 2004) .
The TGF-b super family contains several growth and differentiation factors, such as TGF-b 1-3, Activins, bone morphogenic proteins (BMP) and Nodal. TGF-b, Activin and Nodal bind to and activate type I and type II TGF-b serine-threonine kinases, which then activate downstream regulatory Smad proteins by phosphorylation. Phosphorylated Smad2 and Smad3 trimerize with Smad4 and translocate from the cytoplasm to the nucleus where they act as transcriptional activators of TGF-b target genes (Kawabata et al., 1998; Massague, 2000) . TGF-b performs a pivotal role during embryogenesis, development and tumorigenesis. TGF-b is a potent growth inhibitor of most types of epithelial cells, and perturbation of TGF-b signaling has been shown to contribute to the progression of various tumors (Blobe et al., 2000) . Oncogenes, such as c-Ski/SnoN (Akiyoshi et al., 1999) , c-Myc (Akiyoshi et al., 1999) and Evi-1 (Kurokawa et al., 1998) cause malignant transformation in part by repressing the TGF-b signaling pathway. TGF-b functions as a tumor suppressor in epithelial cells and during the early stages of tumor formation (Wakefield and Roberts, 2002) . Smad3 has been shown to interact with different signal transduction pathways by binding to various transcriptional proteins in these pathways (Moustakas et al., 2001) . For example, it has recently been demonstrated that Smad3 can interact with p53 (Cordenonsi et al., 2003) , Lef-1 (Labbe et al., 2000) , estrogen receptor (Moustakas et al., 2001; Wu et al., 2003) , Disabled-2 (Hocevar et al., 2001) and HEF-1 (Liu et al., 2000) .
TGF-b or BMP induces the expression of several genes that are also known target genes for Notch1, such as Hes-1 (Blokzijl et al., 2003) , Hey1 (Zavadil et al., 2004) , Hes-5 (Takizawa et al., 2003) , Herp2 (Itoh et al., 2004) and the Notch ligand Jagged1 (Zavadil et al., 2004) . However, information as to whether Notch1 or Notch4 can modify the TGF-b signaling pathway and the response of cells to TGF-b is limited. Rao and Kadesch (2003) have recently shown that overexpression of Notch1ICD in mink lung Mv1Lu epithelial cells but not other cells such as C2C12 or NIH 3T3 indirectly deregulates c-Myc expression and can thereby render Mv1Lu epithelial cells resistant to TGF-b growthinhibitory signals. Blokzijl et al. (2003) have reported that Notch1ICD worked synergistically with TGF-b to activate a multimerized CAGA element from the PAI-1 promoter in C2C12 cells. However, it was not shown that a target gene of TGF-b was synergistically upregulated by Notch1ICD at the mRNA and/or protein level.
We present evidence in the present study demonstrating that Notch4ICD attenuates TGF-b signaling in several cell types. Cells expressing the activated form of the Notch4 receptor (ICD4) were resistant to the growth-inhibitory effects of TGF-b. This inhibition is mediated through the interaction of ICD4 with Smad3 and Smad4 and the subsequent attenuation of the ability of TGF-b to activate promoters that contain a Smadbinding element (SBE). A consequence of these interactions is the inhibition of the TGF-b signaling pathway that may significantly predispose mammary epithelial cells to the oncogenic activity of ICD4. Consistent with this hypothesis is our demonstration that treatment of MCF-7 breast cancer cells with a g-secretase inhibitor (GSI), which can block presenillin-induced cleavage of the endogenous Notch4 receptor to ICD4, can sensitize MCF-7 cells to the growth-inhibitory effects of TGF-b.
Results
Activated ICD4 attenuates TGF-b-induced growth inhibition of mammary epithelial cells TGF-b is a tumor suppressor, which can inhibit cell proliferation (Miyazono, 2000) . As a first step towards understanding the molecular events involved in ICD4-induced tumorigenesis, we examined the effect of TGF-b on cells expressing ICD4. The effect of TGF-b1 on the growth of EpH4 mouse mammary epithelial cells was compared with EpH4 cells stably transfected with a vector expressing ICD4 (EpH4-ICD). After 7 days of TGF-b treatment, EpH4 cells showed a dose-dependent inhibition (approximately 60%) of cell growth, whereas growth of EpH4-ICD-expressing cells were significantly less inhibited (30%) (Figure 1a) . Colony-forming assays on plastic using these same cell lines showed a similar effect after TGF-b treatment (data not shown) with the EpH4-ICD cells being refractory (approximately 50%) to the ability of TGF-b to inhibit colony formation on plastic.
To further define the regions of the ICD4 that are required to attenuate the growth-inhibitory effect of TGF-b in mammary epithelial cells, we compared the growth of HC-11 mouse mammary epithelial cells that were expressing either a full-length ICD4 or a truncated form of ICD4 that lacks the RAM23 region (dRAM-ICD4). Both cell lines were more resistant to the growth-inhibitory effects of TGF-b compared to wild-type HC-11 cells or empty vector-transfected HC-11 cells (Figure 1b ). This suggests that the RAM23 region of ICD4 is not necessary to confer resistance to TGF-b-associated cell growth inhibition.
We treated EpH4 control cells and EpH4-ICD cells with or without TGF-b and used bromodeoxyuridine (BrdU) to measure DNA synthesis to study the effects of ICD4 on cell proliferation (Cordenonsi et al., 2003) ( Figure 1c 
ICD4 inhibits TGF-b-induced PAI-1 gene expression
Transcription and translation of PAI-1 is strongly induced by TGF-b and is often used as a marker for TGF-b responsiveness in mammalian cells (Dennler et al., 1998; Feng et al., 1998) . To determine whether ICD4 inhibits TGF-b target gene expression, we treated HC-11 and HC-11-ICD4 cells with or without TGF-b (2 ng/ml) for 0-4 h. As expected, TGF-b induced PAI-1 mRNA expression in HC-11 cells (Figure 2a) . However, ICD4-expressing HC-11 cells showed only 30% PAI-1 expression as compared to HC-11 wild cells (Figure 2a ) after treatment with TGF-b.
To determine whether ICD4 can affect TGF-b signaling in nonmammary epithelial cells, we cloned the ICD4 or dRAM-ICD4 into the GeneSwitch System (Invitrogen) and stably transfected these vectors into NIH3T3 cells. ICD4 or dRAM-ICD4 protein expression can be induced after 16 h treatment with 10 nM mifepristone (Invitrogen). dRAM-ICD4 NIH3T3 cells exhibited 10% PAI-1 protein expression after TGF-b treatment as compared to NIH3T3 cells (Figure 2b ). ICD4 NIH3T3 cells gave a similar result (data not shown), indicating that ICD4 attenuation of TGF-b signaling is independent of the cell type.
ICD4 interacts with Smad2, Smad3 and Smad4
Since ICD4 attenuates the TGF-b-induced growth arrest and appears to do so through a RAM23-independent mechanism, we speculated that one or more members of the Smad family directly interact with ICD4. Interactions between the Smads and ICD4 was assessed by coimmunoprecipitation using a Flag-tagged Smads and immunobloting for V5-antibody in Bosc23 cells transiently transfected with the appropriate expression vectors. As shown in Figure 3a , Smad2, Smad3 or Smad4 could bind to ICD4. However, it appeared that Smad3 bound with a higher affinity to ICD4 than to either Smad2 or Smad4. Similar binding was also detected in a reciprocal experiment, in which the V5-tagged ICD4 were used to pull down the Flag-tagged Smad2, Smad3 and Smad4 (data not shown).
To determine whether this interaction with Smad3 could also be detected in vivo, we prepared protein extracts from mammary tissue of pregnant FVB/N mice and from mammary tumors of WAP-ICD4 mice. The WAP-ICD4 mice express ICD4 under the control of the whey acidic protein (WAP) promoter (Smith et al., 1995) . Protein was coimmunoprecipitated using an anti-ICD4 antibody, 341 (Smith et al., 1995) and probed with an anti-Smad3 antibody. As seen in Figure 3b , both control (FVB/N) and WAP-ICD4 express Smad3, while only WAP-ICD4 mice express ICD4. Similar to the in vitro data, Smad3 was also found to make a complex with the ICD4 in the WAP-ICD4 transgenic mammary tumor extracts.
RAM23 domain of ICD4 is not responsible for binding to Smad3
As expression of the truncated dRAM-ICD4 in HC-11 cells was also able to promote resistance to the growth- Figure 4b , both the full-length ICD4 and dRAM-ICD4 could bind to Smad3. Thus, the RAM23 domain is not required for the binding of Smad3 to the ICD4.
ICD4 interacts with the MH2 domain of Smad3
Smad3 has two conserved domains, the N-terminal Mad homology 1 (MH1) domain and the C-terminal Mad homology 2 (MH2) domain (Figure 5a ). The MH1 domain regulates nuclear import and transcription by binding to DNA (Moustakas et al., 2001) . It also interacts with nuclear proteins. The MH2 domain regulates Smad oligomerization, recognizes Type I receptors and interacts with cytoplasmic adaptors and several transcriptional factors such as p300 (Moustakas et al., 2001) . To ascertain which domain of Smad3 binds to ICD4, we cotransfected a HaHis-tagged ICD4 expression vector (Wu et al., 2001 ) with a Flag-tagged MH1 Smad3 or a Flag-tagged MH2 Smad3 expression construct into Bosc 23 cells. The extracts were immunoprecipitated with an anti-Flag antibody to pull down the Smad3 proteins and immunobloted with anti-ICD4 antibody. As seen in Figure 5b , Smad3 interacts with ICD4 through its MH2 domain. ICD4 expression has no effect on TGF-b-induced phosphorylation of Smad2 or Smad3
TGF-b rapidly induces phosphorylation of Smad2 and Smad3. This is essential for activation of these proteins so that they can trimerize with Smad4 and is translocated to the nucleus. To determine whether ICD4 attenuates TGF-b signaling by impairing phosphorylation of Smad2 or Smad3, we examined their phosphorylation state in HC-11 and HC-11 ICD4 cells treated with TGF-b for 30 min to 24 h. We found that there was no significant difference in TGF-b-induced phosphorylation of either Smad2 or Smad3 in cells with or without ICD4 expression ( Figure 6 ).
ICD4 inhibits TGF-b signaling pathway through Smad3
We next determined whether the interaction between ICD4 or dRAM-ICD4 and Smad3 could affect canonical TGF-b signaling. A TGF-b-sensitive luciferase construct, 3TP-luc, which contains TGF-b-response elements from the plasminogen activator inhibitor-1 and collagenase promoters (Wrana et al., 1992) , as well as an artificial promoter, 4 Â SBE-luc, containing four Smad3/Smad4-binding consensus sequences (SBE: GTCTAGAC) (Zawel et al., 1998) were transiently transfected together with ICD4 or dRAM-ICD4 expression constructs into either EpH4 or 293T/17 cells. Expression of either ICD4 or dRAM-ICD4 inhibited the TGF-b-induced 3TP-luc activity by approximately 50% in both EpH4 (Figure 7a ) and inhibited the TGFb-induced 4 Â SBE activity by 70% in 293 T/17 cells (Figure 7b ). Similar results were also observed in HC-11 and HC-11 ICD4 cells (Figure 7c ). To determine whether ICD4 and Smad3 act synergistically or competitively on TGF-b/Activin-dependent signaling, we transfected Smad3 or ICD4 and 4 Â SBEluc expression vectors into the HC-11 cells. As shown in Figure 7c , Smad3 activates 4 Â SBE-luc expression while ICD4 inhibits 4 Â SBE-luc expression. Different amounts of ICD4 or Smad3 expression vectors were cotransfected with the same amount of 4 Â SBE-luc into HC-11 cells. We found that ICD4 could inhibit by 70% 4 Â SBE-luc activities that was induced by TGF-b and Figure 8a (compare the upper two panels).
As shown in Figure 8b , MCF-7 cells also express endogenous Notch4 and ICD4. To test whether endogenous Notch4 signaling was associated with the resistance of MCF-7 cells to TGF-b-induced growth arrest, we blocked the processing of wild-type Notch4 to the ICD4 form with GSI ( Figure 8b ). As expected, treatment of MCF-7 cells with GSI increased their sensitivity to TGF-b-induced growth arrest (Figure 8a , compare lower two panels and 8c).
Differences between Notch1ICD (ICD1) and Notch4ICD (ICD4) signaling in C2C12 cells
To determine whether there are biological differences between ICD1 and ICD4 on modulating the TGF-b signaling pathway, we cotransfected human ICD1 or mouse ICD4 with TGF-b luciferase reporter constructs SBE or P(CAGA)9 into C2C12 cells. We found that ICD4 suppressed both SBE and P(CAGA)9 luciferase activities in C2C12 cells, whereas Notch1 does not significantly affect TGF-b signaling in these cells ( Figure  9a and b). However, ICD1 was found to attenuate TGFb signaling in HC-11 mammary epithelial cells but not in NIH3T3 cells, suggesting that the inhibitory effects of ICD1 and ICD4 are cell line-dependent (data not shown). 
Discussion

Effects of TGF-b1 or BMP-2 on Notch signaling during development
Two publications (Blokzijl et al., 2003; Takizawa et al., 2003) have recently shown that TGF-b1 can regulate expression of the Notch1 target genes, Hes1 (Blokzijl et al., 2003) and Hey1 (Zavadil et al., 2004) and the Notch ligand, Jagged1 (Zavadil et al., 2004) during embryonic development and during TGF-b-induced epithelial-to-mesenchymal transition (EMT). In Blokzijl's study (2003) (Takizawa et al., 2003) and Herp2 (Itoh et al., 2004) . Takizawa et al. (2003) showed that BMP2 enhances the expression of Hes5 in mouse neuroepithelial cells. The Hes5 promoter has two BMP SBE sites. However, Smad1 was found to only weakly interact with ICD1. Itoh et al. (2004) reported that the ICD1 target gene Herp2 is synergistically induced by BMP6 and ICD1. The Herp2 promoter has two CSL-binding elements and multiple GC-rich palindromic sites that contain BMP co-SBE sites (Korchynskyi and ten Dijke, 2002) .
Effect of Notch on TGF-b signaling during mammary development and tumorigenesis
In the present study we have shown that ICD4 expression attenuates TGF-b-induced growth inhibition in HC-11 and EpH4 mammary epithelial cells as well as inhibits PAI-1 mRNA and protein expression in HC-11 and NIH3T3 cells. In addition, ICD4 attenuates TGFb-induced transcription from the 3TP-luc reporter vector and a 4 Â SBE reporter vector. Evidence was presented that Smad2, Smad3 and Smad4 can physically interact with the ICD4 both in vitro and in vivo and that interaction between Smad3 and the ICD4 does not block phosphorylation of Smad3. Further, this interaction does not require the RAM23 region of the ICD4. Others have reported that activated Notch1 or Notch4 can affect TGF-b signaling. For instance, Uyttendaele et al. (1998) have shown that ICD4 can block TGF-b1-induced branching morphogenesis in TAC-2 mouse mammary epithelial cells. In their study, the minimal region of the ICD4 required for this activity is the RAM23 and the CDC10/Ankrin repeats. The molecular mechanism by which ICD4 signaling affects branching morphogenesis in response to TGF-b1 is not known and may be different than the pathway described here with Smad3 since the RAM23 region of the ICD4 was required for blocking TGF-b-induced branching morphogenesis in TAC-2 cells. Likewise, Rao and Kadesch (2003) showed that overexpressing ICD1 in Mv1Lu epithelial cells but not in other cell lines such as C2C12 or NIH 3T3 could indirectly enhance c-Myc expression and thereby render Mv1Lu epithelial cells resistant to TGF-b growth-inhibitory signals. In the case of HC-11 cells, we did not find that ICD4 expression upregulated c-Myc expression compared to HC-11 cells (data not shown). In Blokzijl et al. (2003) , mouse Notch1ICD functioned synergistically with TGF-b to activate a multimerized CAGA element from the PAI-1 promoter in C2C12 cells. We found that Notch4ICD suppressed both SBE and P(CAGA)9 in three different cell lines. However, the Notch1ICD affect on TGF-b signaling is cell line-dependent, Notch1ICD can inhibit TGF-b signaling in HC-11 cells, but not in NIH3T3 cells or C2C12 cells. We did not find results similar to Blokzijl et al demonstrating that Notch1ICD can synergistically interact with TGF-b to activate P(CAGA)9-luc activity. A possible explanation for this difference is that we used human Notch1ICD and not mouse Notch1ICD. Additionally, there are some differences between Notch1ICD and Notch4ICD. In fact, Notch4ICD is smaller than Notch1ICD and lacks the transcriptional activation domain (TAD) and cytokine response (NCR) sequence found in the Notch1ICD (Uyttendaele et al., 1996; Allenspach et al., 2002) . Shimizu et al. (2002) have reported that there is functional diversity among the Notch receptors. The transcriptional activities of Notch1ICD, Notch2-ICD and Notch3ICD were markedly different from each other, and the activities of Notch1ICD or Notch3ICD were reduced by coexpression of Notch2ICD. Fan et al. (2004) also showed that Notch1ICD and Notch2ICD can have opposite effects on the growth of a single tumor type. Moreover, Notch1 acts as an oncogene in some carcinomas (Capobianco et al., 1997; Weijzen et al., 2002; Kiaris et al., 2004) , and as a tumor suppressor (Nicolas et al., 2003; Fan et al., 2004) in others. Our results taken together with these are consistent with the conclusion that the Nocth effect on TGF-b signaling is cell line-dependent and Notchdependent.
Our results show that the RAM23 region of ICD4 is not necessary to confer resistance to TGF-b-induced cell growth inhibition or to bind Smad3. Since a RAM23-independent pathway can disrupt or attenuate TGF-b signaling, this may be a factor that is essential for promoting early stages of tumorigenesis by activated ICD4 in the mammary gland. Consistent with this premise is our observation that blockage of endogenous Notch4 signaling in MCF-7 breast cancer cells, which are normally resistant to TGF-b cell growth inhibition (Xie et al., 2002) , with GSI treatment develop a sensitivity to TGF-b-induced growth inhibition. Furthermore, preliminary results of a genetic cross between WAP-ICD4 and WAP-TGF-b1 transgenic mice (our unpublished data) in which we have compared the latency and frequency of mammary tumors in WAP-ICD4 mice with bitransgenic mice that express both WAP-ICD4 and WAP-TGF-b1 are also consistent with this speculation and further confirms our in vitro data. These bitransgenic mice develop mammary tumors with the same latency and frequency as the WAP-ICD4 mice, demonstrating that the TGF-b signaling pathway is compromised in ICD4-expressing mammary epithelial cells. In conclusion, the inhibitory effect of ICD4 on Smad3-dependent signaling may be biologically significant since overexpression of ICD4 is a potent oncogene in the mouse mammary gland and this oncogenic activity may depend upon the ability of ICD4 to function as antagonist of TGF-b signaling during the early stages of tumor formation where TGF-b normally functions as a tumor suppressor.
Materials and methods
Expression vectors
Flag-tagged mouse Smad3, Smad3-N and Smad3-C expression vectors were kindly provided by Tongwen Wang (Virginia Mason Center, WA, USA) (Liu et al., 2000) . Flag-tagged human Smad2, Smad3 and Smad4 expression vectors and adenoviral constructs encoding mouse Smad2, Smad3 and Smad4 were gifts from Kohei Miyazono, University of Tokyo (Fujii et al., 1999) . Notch4/Int3 intracellular domain (ICD4) and human dRAM23-ICD4 cDNA (Imatani and Callahan, 2000) were ligated into pcDNA 3.1 pEF1/V5His TOPO TA expression vector (Invitrogen, CA, USA). The ICD4 and dRAM-ICD4 were also cloned into the GeneSwitch System (Invitrogen) and stably transfected into NIH3T3 cells. ICD4 and dRAM-ICD4 protein expression was induced for 16 h with 10 nM mifepristone in NIH3T3 cells. The HAHis-tagged mouse ICD4 was kindly provided by Jan Kitajewski, Columbia University (Wu et al., 2001) . Human Notch1ICD was kindly provided by Anthony J Capobianco, University of Pennsylvania (Capobianco et al., 1997) .
Cell culture, transfection and reagents
The Bosc 23 cell line, C2C12 and MCF-7 were purchased from ATCC (Manassas, VA, USA). Stable transfectants of pEF-1 control vector, pEF-ICD4, pEF1-dRAM-ICD4 in HC-11 mouse mammary epithelial cells (a gift from Dr Nancy Hynes, Friedrich Miescher Institute, Basel, Switzerland) and EpH4 mouse mammary epithelial cells were cultured and stably transfected as described (Imatani and Callahan, 2000; Wechselberger et al., 2001) . Colonies were selected and tested by RT-PCR and Western blot analysis (Bianco et al., 2002) for transgene expression. TGF-b1 was purchased from R&D (Minneapolis, MN, USA). g-Secretase inhibitor (L-685, 458) was purchased from Calbiochem (San Diego, CA, USA).
Analysis of cell growth inhibition by TGF-b1 in vitro
In vitro growth inhibition by TGF-b1 was assessed in EpH4 wild-type and EpH4 ICD4 stable cell lines as well as HC-11, HC-11pEF1, HC-pEF1-ICD4, HC-11 pEF1-dRAM-ICD4 cell lines. Briefly, each of the cell lines were seeded into 12-well plates at 1 Â 10 4 cells/well. The following day, the cells were treated with 0.4, 2, 10 or 50 ng/ml of TGF-b1 (R&D, Minneapolis, MN, USA) for 7 days, and then counted. The ratio of cell number of each treatment with TGF-b1 and the cell number of control cells without TGF-b treatment is expressed as the cell growth inhibition.
BrdU incorporation assay
EpH4 and EpH4-ICD4 cells were plated onto cover slips with or without TGF-b1 (2 ng/ml) for 48 h. For BrdU incorporation, cells were labeled with 10 mM BrdU (Roche, Indianapolis, IN, USA) for 30 min and processed according to BrdU labeling and detection kit (Roche) instructions. Cells were also treated with antifade/4,6-diamino-2-phenylindole (DAPI) staining and then scored for BrdU-positive cells. The experiments were performed twice, each time in duplicate.
RT-PCR analysis of PAI-1 and GAPDH in HC-11 pEF-1 and HC-11 ICD4 cells Total RNA was isolated from HC-11 pEF-1 and HC-11 ICD4 cells treatment with TGF-b1, cDNA synthesis and PCR was performed as described . RT-PCR primers are described elsewhere (Bianco et al., 2002) : mouse PAI-1: 5 0 -atgagatcagtactgcggatgccatct and 5-gcacagagacggtgctgccat cagact-3 0 (accession number: M16006); glyceraldehyde-3-phosphate dehydrogenase (GAPDH): 5 0 -cccttcattgacctcaac tac-3 0 and 5 0 -ccaccttcttgatgtcatcat-3 0 .
Protein extraction, Western blotting and antibodies
Cells were lysed as previously described (Bianco et al., 2002; Sun et al., 2002) . Protein (50 mg) was subjected to SDSpolyacrylamide gel electrophoresis (Invitrogen, Carlsbad, CA, USA) as described (Bianco et al., 2002; Sun et al., 2002) . The antibodies used were anti-V5 (Invitrogen, 1 : 5000), anti-Flag-HRP (Sigma, St Louis, MO, USA; 1 : 1000), anti-Notch4 (Upstate, Charlottesville, VA, USA; 1 : 1000), anti-P-Smad2 (Upstate, 1 : 1000), anti-Smad2 (Zymed, 1 : 1000), anti-Smad3 (Zymed, South San Francisco, CA, USA; 1 : 1000), anti-PSmad3 (kindly provided by Dr Michael Reiss), anti-Smad2/ 3(Santa Cruz, 1 : 250), anti-Lamin A/C (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; 1 : 250) and anti-PAI-1 (American Diagnostica Inc., 1 : 2000).
Coimmunoprecipitation of ICD4 and Smad2, Smad3 or Smad4
Bosc 23 cells (1 Â 10 6 cells on 60-mm-diameter plates) were transfected with 2 mg HaHis-ICD4 expression vector using Lipofectamine reagent (Invitrogen) according to the manufacturer's instruction. After 16 h, cells were infected with an empty adenovirus or an adenovirus containing mouse Smad2, Smad3 or Smad4 genes at a multiplicity of infection of 5 in medium containing 4 mg/ml of polybrene (Sigma). At 72 h after transfection, the cells were lysed for 20 min with 0.5 ml lysis buffer as previously described (Zhou et al., 2000) for 20 min. Total protein (1 mg) was incubated with 30 ml of anti-V5 antibody conjugated to agarose beads (Sigma) overnight at 41C. The Agarose was washed four times with 0.5 ml lysis buffer. Western blotting was analysed as described (Bianco et al., 2002) with anti-V5 (Invitrogen) or anti-Flag horseradish peroxidase-conjugated antibody (Sigma). Similarly, 1 mg of total protein lysates were incubated with 30 ml anti-Flag Agarose (Sigma) gel matrix overnight at 41C. The Agarose Notch4 inhibition of TGF-b signaling Y Sun et al was then washed with 0.5 ml lysis buffer four times, and the samples were analysed as described above.
Coimmunoprecipitation of ICD4 and Smad3, N-Smad3 (MH1) or C-Smad3 (MH2)
Bosc23 cells (1 Â 10 6 cells on 60-mm-diameter plates) were transfected with 2 mg V5His-ICD4 expression vector alone or with 2 mg Flag-Smad3, Flag-Smad3 (MH1) and Flag-Smad3 (MH2) using LipofectAMINE reagent (Invitrogen). Cells were lysed 72 h after transfection, and coimmunoprecipitation was processed as described above.
Coimmunoprecipitation of ICD4 and Smad3 from Wap-ICD4 transgenic mammary gland Mammary glands from pregnant (day 15) FVB/N or Wap-ICD4 mice were lysed with lysis buffer as described above. The 341 rabbit anti-ICD4 antibody (Smith et al., 1995) was conjugated to protein G-agarose (Roche) by adding 4 mg of 341-50 ml protein G-agarose in 1 ml of lyses buffer at 41C with rotation for 2 h. Excess antibody was removed by washing in lysis buffer and centrifugation at 12 000 g for 30 s four times. After the last wash, the supernatant was removed and a 1 ml sample containing 2 mg total protein was added to the antibody bound to the Protein G-agarose. This complex was rotated overnight at 41C. The next day, the complexes were washed three times. The Western blots were probed with Anti-Smad3 (Santa Cruz, 1 : 250) and anti-Notch4 antibody (Santa Cruz, 1 : 250) to detect Smad3 and ICD4 in 341 immunoprecipatates.
Luciferase assay
HC-11, EpH4 and 293T/17 cell lines were transfected with 1 mg ICD4 pEF-1 expression vector and 0.5 mg 3TP-luc (Wrana et al., 1992) or 4xSBE-luc (Zawel et al., 1998) using lipofectamine or lipofectamine 2000 regent (Invitrogen). The total amount of DNA for each transfection was adjusted to 2 mg using pEF1 control vector (Invitrogen). Renilla luciferase control reporter vector (pRL-TK) (Promega, Madison, WI, USA) was cotransfected in the cells to normalize for transfection efficiency. At 5 h after transfection, complete media were added to the cells. At 48 h after transfection, cells were lysed and luciferase activity was determined by using a Dual-luciferase reporter assay system (Promega), according to the manufacturer's manual. All assays were performed in triplicate and represent a mean (7s.e.) of three independent transfections.
